Venous indications

Fondaparinux, the factor Xa-binding pentasaccharide (Arixtra, MW 1,728 Da), is prepared synthetically, unlike UFH, LMWH and danaparoid, which are obtained from animal sources. Despite only inactivating free factor Xa, clinical trials indicate that fondaparinux is an effective antithrombotic agent, both for venous thromboembolism prophylaxis and treatment, as well as for acute coronary syndrome and ST elevation myocardial infarction [4]. 

CHD is the leading cause of death among women in the United States. Retrospective data indicated that HRT was associated with a decrease in risk of CHD by 30% to 50%.21 However, the results of recent RCTs demonstrate that HRT does not prevent or treat CHD in women and that it actually may cause an increase in CHD events. The HERS, published in 1998, was the first RCT conducted in women with established CHD. This trial demonstrated an increased incidence of CHD events within the first year of treatment with HRT and an increased risk of venous thromboembolism (VTE) and gallbladder disease. There was a trend of decreasing incidence... 

The partial oxygen pressure, p02, is particularly significant in metabolic processes of cells, and its variation from normal values often indicates pathologies (ischemic diseases, strokes, tumors). Accurate and localized measurements of the oxygen concentration are also desirable for differentiation between venous and arterial blood, or for cerebral mapping of task activation. In the past, invasive methods were used involving oxygen-sensitive electrodes which had to be placed directly in the blood or tissue and could only offer p02 from a few body points. 

Risk assessment. The Perbellini model successfully described alveolar air and venous blood concentrations of -hexane following inhalation exposure in humans. Simulations indicated that exposure to 50 ppm for an 8-hour-workday, 5-day workweek would result in a gradual accumulation of -hexane in body fat which is not completely cleared during the weekend. 

Cmax and Tmax values are for peripheral venous blood unless otherwise indicated... 

In the case of immunoglobulin, microarray data indicated the opposite effect that the Fc-receptor is elevated in chronic MS but not in acute lesions. Using Fcy-receptor knockout mice, the disease was found to be absent. Inter-venous immrmoglobulin therapy in the EAE mouse model was reported (see Lock, 2002, Reference 29). In summary. Lock et al. were able to apply the results of microarray-based gene expression clustering of a human disease pathological state (acute vs. chronic MS) to successfully identify fherapeutic targets for an animal model (EAE) potentially applicable to the human condition. 

Serum alkaline phosphatase elevations have been reported following administration of salt-poor albumin (B5). Placenta is very rich in a heat-stable alkaline phosphatase, and albumin prepared from placental blood has a high activity of this enzyme. In one cirrhotic patient who received 1-6 units per day of albumin obtained from pooled human blood and/or human placenta, the alkaline phosphatase before infusion was 5 Bodansky units and by the thirteenth day of administration had reached a value of 160 units. The physician administering the albumin at first thought the patient was having a severe toxic liver reaction and stopped the therapy. The alkaline phosphatase then started to go down and within 10 days returned to normal levels. Analysis of the albumin indicated that it contained 470 units of alkaline phosphatase activity and was probably responsible for the observed elevations in the serum enzyme activity. Albumin prepared from venous blood did not cause an alkaline phosphatase elevation, but placenta-albumin caused elevations with a half-life of about 8 days (Ml). 

Levels of fasting venous plasma lactate above the upper limit of normal but less than 5 mmol/L in patients taking metformin do not necessarily indicate impending lactic acidosis and may be explained by other mechanisms, such as poorly controlled diabetes or obesity, vigorous physical activity, or technical problems in sample handling. 

Furthermore, central-acting antimuscarinic drug are effective in the treatment of motion sickness. In this indication the alkaloid scopolamine has been shown to be effective. It can be applied orally, intra venously or via a transdermal therapeutic system. 

Ceprotin, can be given. Ceprotin is of course also indicated for patients with severe congenital Protein C deficiency for the prevention and treatment of venous thrombosis and purpura fulminans. 

Administration of fibrinolytic drugs by the intravenous route is indicated in cases of pulmonary embolism with hemodynamic instability, severe deep venous thrombosis such as the superior vena caval syndrome, and ascending... 

In present times, because of early mobilization and shorter stays in hospital, venous thrombosis in the legs and resulting pulmonary embolism has declined to a large degree. In persons with acute myocardial infarction, prophylactic low-dose heparin has reduced the incidence of venous thrombosis in the legs. It is considered as a reasonable alternative to warfarin in selected patients. Preventive anlicoagulalion may be indicated in some cases to prevent strokes due to left ventricular mitral thrombi embolizing in tire brain. 

In every 100 milliliters of arterial blood, there is a total of 48 milliliters of free and comhined CO . In venous blood of resting humans, there is about 5 milliliters more than this. Only about 1/20 of the carbon dioxide is uncombined, a fact which indicates that there is a specialized mechanism, aside from simple solulion, for the transport of CO in the blood. 

In summary, it must be noted that in spite of the wide-spread utility of the methods of ionic immobilization of heparin it is difficult to consider a long-term use of the resultant HCP. All of the reported results indicate that after the contact of HCPs with blood and other physiological media, heparin is qurite rapidly desorbed from the polymeric surface. This does not restrict the use of such heparin-containing polymers for the purposes of a short-term contact with blood. Today such materials are already used to manufacture catheters for perito-venous shunting in Japan, USA, France, and Sweden85 87). 

The Medicines Commission of the UK has reviewed all currently available relevant data and has confirmed that the incidence of venous thromboembolism is about 25 per 100 000 women per year of use (21). The incidence of venous thrombembolism in users of second-generation combined oral contraceptives is about 15 per 100 000 women per year of use. This indicates a small excess risk... 

Cyproterone acetate in combination with ethinylestra-diol is indicated for the treatment of women with severe acne and moderately severe hirsutism. This product has been associated with a greater risk of venous thromboembolism than oral contraceptives. However, in a rigorous case-control study the risk of venous thromboembolism with cyproterone acetate + ethinylestradiol was not significantly greater than the risk in women who took conventional oral contraceptives (25). 

England that the Committee on Safety of Medicines had written to prescribers in 1995 stating that three unpublished studies on the safety of combined oral contraceptives in relation to venous thromboembolism had indicated about a two-fold increase in the risk of such conditions compared with the preceding generation of products. This issue of a two-fold increase became crucial to the case. For reasons of causation, as the Judge put it, the claimants had accepted the burden of proving that the increase in risk was not less than two-fold. 

---